中国现代神经疾病杂志 ›› 2017, Vol. 17 ›› Issue (2): 151-155. doi: 10.3969/j.issn.1672-6731.2017.02.012

• 综述 • 上一篇    下一篇

2 多奈哌齐治疗轻中度阿尔茨海默病作用机制研究进展

李欣欣, 张云云, 王滨   

  1. 214000 南京医科大学附属无锡人民医院神经内科(李欣欣),老年病科(张云云、王滨)
  • 出版日期:2017-02-25 发布日期:2017-02-07
  • 通讯作者: 王滨(Email:wangbwxry@sohu.com)
  • 基金资助:

    南京医科大学科技发展基金重点项目(项目编号:2014NJMUZD059)

Research progress of donepezil for treating mild to moderate Alzheimer's disease

LI Xin-xin1, ZHANG Yun-yun2, WANG Bin2   

  1. 1Department of Neurology, 2Department of Geriatrics, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi 214000, Jiangsu, China
  • Online:2017-02-25 Published:2017-02-07
  • Contact: WANG Bin (Email: wangbwxry@sohu.com)
  • Supported by:

    This study was supported by Science and Technology Development Foundation Key Project of Nanjing Medical University (No. 2014NJMUZD059).

摘要:

多奈哌齐是第2 代胆碱酯酶抑制剂,对轻中度阿尔茨海默病有较好疗效。近年关于多奈哌齐作用机制的相关研究较为丰富,本文拟就我国阿尔茨海默病诊断与治疗现状和多奈哌齐治疗轻中度阿尔茨海默病作用机制研究进展进行概述。

关键词: 阿尔茨海默病, 哌啶类, 茚满类, 综述

Abstract:

Donepezil is the second generation of cholinesterase inhibitors (ChEIs), which has a good effect on mild to moderate Alzheimer's disease (AD). In recent years, there were a lot of studies on the mechanism of donepezil. This paper mainly introduces the diagnosis and treatment situation of AD in China, and the action mechanism of donepezil in the treatment of mild to moderate AD.

Key words: Alzheimer disease, Piperidines, Indans, Review